ストックスクリーナーアプリを入手
11.68
2.18%
-0.26
アフターアワーズ：
11.60
-0.08
-0.68%
前日終値:
$11.94
開ける：
$11.93
24時間の取引高:
114.94K
Relative Volume:
0.49
時価総額：
$437.30M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.83%
1か月 パフォーマンス:
+9.06%
6か月 パフォーマンス:
-44.30%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.67
$12.31
1週間の範囲:
$10.63
$12.42
52週間の値動き範囲:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
ORKA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
11.68 | 429.44M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-10-11 | 開始されました | Stifel | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | Leerink Partners | Outperform |
| 2024-09-16 | 開始されました | TD Cowen | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2018-02-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 開始されました | Dawson James | Buy |
すべてを表示
Oruka Therapeutics Inc (ORKA) 最新ニュース
Oruka Therapeutics Holds Annual Stockholders Meeting - TipRanks
Jane Street Group LLC Buys New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Has Positive Estimate for ORKA Q2 Earnings - Defense World
Northern Trust Corp Acquires Shares of 64,044 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial - MSN
H.C. Wainwright maintains Buy on Oruka stock, $45 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on Oruka stock, $45 target - Investing.com UK
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at BTIG Research - Defense World
BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target - marketscreener.com
BTIG sets $44 price target on Oruka Therapeutics stock - Investing.com UK
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Oruka Therapeutics begins trial for psoriasis treatment By Investing.com - Investing.com South Africa
Oruka Therapeutics begins trial for psoriasis treatment - Investing.com Australia
Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment - marketscreener.com
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - GlobeNewswire
Revolutionary Psoriasis Treatment Begins Human Trials: Only 2-3 Doses Per Year Needed - Stock Titan
Wedbush Forecasts Reduced Earnings for Oruka Therapeutics - Defense World
What is Wedbush’s Estimate for ORKA FY2029 Earnings? - Defense World
Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) versus Trinity Biotech (NASDAQ:TRIB) Critical Analysis - Defense World
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics Announces Accelerated Clinical Timelines and Strong Financial Position for Psoriasis Programs - Nasdaq
Oruka Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
Oruka Therapeutics, Inc. SEC 10-Q Report - TradingView
Oruka Therapeutics (NASDAQ:ORKA) and Trinity Biotech (NASDAQ:TRIB) Head-To-Head Analysis - Defense World
JPMorgan Chase & Co. Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Barclays PLC Purchases Shares of 74,583 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Issues Negative Estimate for ORKA Earnings - Defense World
Equities Analysts Offer Predictions for ORKA Q1 Earnings - Defense World
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference - GlobeNewswire
Geode Capital Management LLC Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Comparing TNF Pharmaceuticals (NASDAQ:TNFA) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Thursday - Defense World
Vanguard Group Inc. Purchases 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - The AM Reporter
Vanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Acquired by Wellington Management Group LLP - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Charles Schwab Investment Management Inc. Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Fairmount Funds Management LLC Increases Stake in Oruka Therapeu - GuruFocus
Oruka Therapeutics Reports Strong 2024 Financial Results - TipRanks
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance - MSN
Comparing Oruka Therapeutics (NASDAQ:ORKA) & Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Earns “Outperform” Rating from Wedbush - Defense World
We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate - Yahoo Finance
Oruka Therapeutics Inc (ORKA) 財務データ
Oruka Therapeutics Inc (ORKA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):